ViiV Healthcare announced the upcoming presentation of more than 60 abstracts showcased at two conferences this year: the 20 th European AIDS Conference held in Paris, France, from October 15 - 18, and IDWeek 2025, held in Atlanta, Georgia, from October 19-22, according to a recent news release .

“The breadth of our data presented at EACS and IDWeek reinforce the effectiveness of our therapies, the potential promise of our pipeline and our unwavering commitment to meeting the evolving needs of those impacted by HIV,” J ean van Wyk, MBChB, chief medical officer at ViiV Healthcare, said in the news release. “ The CLARITY study, comparing single dose injections of cabotegravir and lenacapavir, offers critical insights into patient and provider preferences, empowering informed decisio

See Full Page